![]()
Glucose Homeostasis in Acromegaly: Effects of Long-Acting Somatostatin Analogues
Reply
![]() |
|
From:
![]() ![]() MinnieChat
|
Glucose Homeostasis in Acromegaly: Effects of Long-Acting Somatostatin Analogues Treatment Posted 11/04/2003 Roberto Baldelli, Claudia Battista, Frida Leonetti, Maria-Rosaria Ghiggi, Maria-Cristina Ribaudo, Antonella Paoloni, Eugenio D'Amico, Elisabetta Ferretti, Roberto Baratta, Antonio Liuzzi, Vincenzo Trischitta, Guido Tamburrano Summary and Introduction Summary Objective: Acromegaly is a syndrome with a high risk of impaired glucose tolerance (IGT) and diabetes mellitus (DM). Somatostatin analogues, which are used for medical treatment of acromegaly, may exert different hormonal effects on glucose homeostasis. Twenty-four active acromegalic patients were studied in order to determine the long-term effects of octreotide-LAR and SR-lanreotide on insulin sensitivity and carbohydrate metabolism.
Design: Prospective study.
Patients: We studied 24 patients with active acromegaly, 11 males and 13 females, aged 50�7 � 12�7 years, body mass index (BMI) 30�1 � 4�8 (kg/m2).
Measurements: All patients underwent an oral glucose tolerance test (OGTT) and 12 also had an euglycaemic hyperinsulinaemic clamp. All patients were evaluated at baseline and after 6 months of somatostatin analogues therapy.
Results: Acromegalic patients showed low M-values in respect to the control group at baseline (P < 0�05), followed by a significant improvement after 6 months of therapy (P < 0�005 vs. baseline). Serum glucose levels at 120 min during OGTT worsened (P < 0�05) during somatostatin analogs therapy in patients with normal glucose tolerance, but not in those with impaired glucose tolerance or diabetes mellitus. This was associated with a reduced (P < 0�05) and 30 min delayed insulin secretion during OGTT. Also, HbA1c significantly deteriorated in all subjects after treatment (4�7 � 0�6% and 5�1 � 0�5%, basal and after six months, respectively, P < 0�005).
Conclusion: In acromegalic patients, somatostatin analogues treatment reduces insulin resistance, and also impairs insulin secretion. This may suggest that the use of oral secretagogue hypoglycaemic agents and/or insulin therapy should be considered rather than insulin sensitizers, as the treatment of choice in acromegalic patients who develop frank hyperglycaemia during somatostatin analogues therapy. You can see the full-text article here: http://www.medscape.com/viewarticle/462811 |
|
View other groups in this category.
| | New Mom Advice Free Gifts & Offers Pregnancy Q&A Infant Care Free Phone Support Free Newsletters |
|
![]() |
To stop getting this e-mail, or change how often it arrives, go to your E-mail Settings.
Need help? If you've forgotten your password, please go to Passport Member Services.
For other questions or feedback, go to our Contact Us page.
If you do not want to receive future e-mail from this MSN group, or if you received this message by mistake, please click the "Remove" link below. On the pre-addressed e-mail message that opens, simply click "Send". Your e-mail address will be deleted from this group's mailing list.
Remove my e-mail address from Pituitary Chat.
|
|
